Sab, A Candidate for Human Degenerative Disease and Therapeutic Sensitivity in Cancer Patent

fiu authors


  • FIU inventors have discovered a method for detecting degenerative diseases in humans without a focus on blood factors and, instead, using protein SAB (or SH3BP5). SAB is a scaffold protein that coordinates signaling components on the outer mitochondrial membrane, which can drive processes such as mitochondrial dysfunction and cell death. Using SAB as a biomarker to organize signaling components and destabilize the integrity of the mitochondrial membrane potential reduces metabolic efficiency and recruits death inducing proteins to the mitochondrial surface. Current clinical screens for degenerative diseases exist at the genetic level. However, using a protein marker in the blood or tissue for the same purpose would be faster, less expensive, and in the case of cancer susceptibility to treatment, using SAB could be an earlier biomarker than those previously used. Benefit Using SAB as a protein biomarker is faster and less expensive SAB may be an earlier biomarker than other proteins when used for cancer susceptibility to treatment Market Application Selective detection of SAB can provide medical insight into the development and progression of human diseases, such as Parkinson, Diabetes, Muscular Dystrophy, Alzheimer, Anyotrophic Lateral Sclerosis, and more IP Number: US 10,078,090 Status: Granted


research area


  • Biomarker
  • Diagnostic
  • Neurodegenerative Diseases
  • SAB (SH3BP5)

patent number

  • US 10,078,090